Sentences with phrase «of pimobendan»

Effect of Pimobendan in Dogs with Preclinical Myxomatous Mitral Valve Disease and Cardiomegaly: The EPIC Study — A Randomized Clinical Trial.

Effect of pimobendan in dogs with preclinical myxomatous mitral valve disease and cardiomegaly: the EPIC Study - a randomized clinical trial.

The EPIC (Evaluation of Pimobendan In dogs with Cardiomegaly) Study marks the largest veterinary cardiology study in history.

The EPIC Study showed that administration of pimobendan resulted in a 15 ‑ month delay in time to primary endpoint compared with dogs receiving placebo.

The aim of this study was to evaluate the efficacy of pimobendan with conventional therapies on survival and reocurrence of pulmonary edema in dogs with congestive heart failure (CHF) caused by myxomatous mitral valve disease (MMVD).

There was no difference in survival between dogs administered standard and low doses of pimobendan, but pimobendan did prevent the reoccurrence of pulmonary edema in a dose - dependent manner.

Combination of pimobendan with a conventional treatment regimen significantly prolonged survival time after an initial episode of pulmonary edema in dogs with CHF caused by MMVD.

O'Grady MR, Minors SL, O'Sullivan ML, Horne R. Effect of pimobendan on case fatality rate in Doberman pinschers with congestive heart failure caused by dilated cardiomyopathy.

The advent of pimobendan has made the use of digoxin far less common.

The EPIC study (Evaluation of Pimobendan In Cardiomegaly) found pimobendan extended the asymptomatic period by an average of 15 months, while dogs that received the drug also lived significantly longer than those receiving a placebo.

Clinical efficacy of pimobendan versus benazepril for the treatment of acquired atrioventricular valvular disease in dogs.

Effect of pimobendan in dogs with preclinical myxomatous mitral valve disease and cardiomegaly: the EPIC Study — a randomized clinical trial.

Effect of oral administration of pimobendan in cats with heart failure.

Efficacy of pimobendan in the prevention of congestive heart failure or sudden death in Doberman Pinschers with preclinical dilated cardiomyopathy (the PROTECT Study).

EPIC showed that administration of pimobendan to preclinical dogs was found to significantly extend the symptom - free period of those dogs» lives by an average of 15 months.1

EPIC examined dogs with stage B2 MMVD and echocardiographic and radiographic evidence of cardiac enlargement to determine whether long - term administration of pimobendan could delay onset of CHF, cardiac - related death, or euthanasia.

The EPIC (Evaluation of Pimobendan In dogs with Cardiomegaly) Study1 analysed whether long - term administration of pimobendan to dogs with stage B2 myxomatous mitral valve disease (MMVD) and echocardiographic and radiographic evidence of cardiac enlargement will delay onset of clinical signs of congestive heart failure (CHF), cardiac - related death, or euthanasia (composite primary endpoint).

Groundbreaking results of the EPIC (Evaluation of Pimobendan In dogs with Cardiomegaly) Study, the largest veterinary cardiology study in history, are now published.

Sixty - four dogs received a standard dose of pimobendan (0.20 — 0.48 mg / kg every 12 hr (q12hr)-RRB-, 49 dogs received a low dose of pimobendan (0.05 — 0.19 mg / kg q12hr) and 84 dogs received conventional therapy alone.

The trial, titled «Effect of Pimobendan in Dogs with Preclinical Myxomatous Mitral Valve Disease (MMVD) and Cardiomegaly» (EPIC), is the largest clinical study ever to be conducted in veterinary cardiology.

This license extension follows the results of a clinical trial — the so called EPIC trial — which studied the effect of pimobendan (the active ingredient in...

Effect of pimobendan or benazepril hydrochloride on survival times in dogs with congestive heart failure caused by naturally occurring myxomatous mitral valve disease: the QUEST study.